The extended use of aromatase inhibitor therapy beyond 5 years remains controversial. However, a new study found that extending letrozole use significantly improves disease-free survival in ...
The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole with tamoxifen as ...
Combination everolimus/letrozole yielded a higher progression-free survival over letrozole alone in a population of patients with hormone receptor (HR)–positive, ERBB2-negative advanced breast cancer.
Since this is Breast Cancer Awareness month I want to share new drugs that have been developed to treat advanced breast ...
This study "demonstrated no improvement in PFS with fulvestrant-palbociclib over letrozole-palbociclib among patients receiving initial systemic treatment for endocrine-sensitive, hormone receptor ...
Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole in breast ...
Tamimi STEPP analysis of the letrozole versus tamoxifen treatment effect across the continuum of AR expression indicated general superiority of letrozole monotherapy, irrespective of AR expression ...
Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer Novartis has presented a final analysis of its phase 3 MONALEESA ...
PMLiVE1mon
Mayer; Robert B. West; William J. Maloney; Christopher H. Contag; Bonnie L. King Letrozole Inhibition of ER+ Breast Cancer Cells is Mediated by Bone Tissues To determine if residual letrozole in ...
The International Tennis Federation announced the suspension on Monday after Errani tested positive for the banned substance letrozole in a test taken in February. At a news conference ...
placebo plus letrozole in postmenopausal women (HR=0.76; p=0.004) 2 Kisqali is the only CDK4/6 inhibitor with proven OS benefit across all three Phase III trials of the MONALEESA program with ...
The sequential use of endocrine agents including the selective estrogen receptor modulators (tamoxifen), aromatase inhibitors (letrozole, anastrozole, and exemestane) and the selective estrogen ...